US Government As Represented by the Secretary of the Army

Other

Bruce L Innis

Kenneth H Eckels

Doria R Dubois

Joseph R Putnak

Charles H Hoke

David Vaughn

Yong Cheol Shin

Hyun Su Kim

Sun Pyo Hong

Sung Hee Lee

Soo Ok Kim

Wang Don Yoo

Niranjan Kanesa-Thasan

Wellington Sun

Niranjan Kanessa-thasan

Sang Bum Moon

Yong Ju Chung

Joseph R Puniak

Niranian Kanesa-thasan

Ashok K Srivastava

Erik A Henchai

Leonard N Binn

Sun Wellington

Joseph B Putnak

The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, dengue-2, dengue-3, and dengue-4 virus.

Multivalent dengue virus vaccine

The present invention provides a method for replicating virus to high titer in cultured mammalian cells by infecting the mammalian cells with the high titer virus strain to obtain infected cells, specifically, attenuated dengue virus strains of serotype 1, 2, 3, and 4. The resulting replicated virus is suitable for use in vaccines and vaccination methods which are also provided by the invention.

Adaptation of virus to vertebrate cells

The present invention provides vaccine compositions of attenuated dengue-4 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-4 virus by administration of attenuated dengue-4 virus.

Attenuated dengue-4 virus vaccine

The present invention provides immunogenic compositions of attenuated dengue-1 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-1 virus by administration of attenuated dengue-1 virus.

Attenuated dengue-3 virus vaccine

The present invention provides vaccine compositions of attenuated dengue-2 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-2 virus by administration of attenuated dengue-2 virus.

Attenuated dengue-2 virus vaccine

An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell is disclosed. A Japanese encephalitis vaccine comprising said attenuated virus is also disclosed.

Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine

Growing community of inventors

Haverford, PA, United States of America

Bruce L Innis